首页> 外文期刊>JAMA: the Journal of the American Medical Association >Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease.
【24h】

Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease.

机译:老年人带状疱疹疫苗和随后发生带状疱疹疾病的风险。

获取原文
获取原文并翻译 | 示例
           

摘要

CONTEXT: Approximately 1 million episodes of herpes zoster occur annually in the United States. Although prelicensure data provided evidence that herpes zoster vaccine works in a select study population under idealized circumstances, the vaccine needs to be evaluated in field conditions. OBJECTIVE: To evaluate risk of herpes zoster after receipt of herpes zoster vaccine among individuals in general practice settings. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study from January 1, 2007, through December 31, 2009, of individuals enrolled in the Kaiser Permanente Southern California health plan. Participants were immunocompetent community-dwelling adults aged 60 years or older. The 75,761 members in the vaccinated cohort were age matched (1:3) to 227,283 unvaccinated members. MAIN OUTCOME MEASURE: Incidence of herpes zoster. RESULTS: Herpes zoster vaccine recipients were more likely to be white, women, with more outpatient visits, and fewer chronic diseases. The number of herpes zoster cases among vaccinated individuals was 828 in 130,415 person-years (6.4 per 1000 person-years; 95% confidence interval [CI], 5.9-6.8), and for unvaccinated individuals it was 4606 in 355,659 person-years (13.0 per 1000 person-years; 95% CI, 12.6-13.3). In adjusted analysis, vaccination was associated with a reduced risk of herpes zoster (hazard ratio [HR], 0.45; 95% CI, 0.42-0.48); this reduction occurred in all age strata and among individuals with chronic diseases. Risk of herpes zoster differed by vaccination status to a greater magnitude than the risk of unrelated acute medical conditions, suggesting results for herpes zoster were not due to bias. Ophthalmic herpes zoster (HR, 0.37; 95% CI, 0.23-0.61) and hospitalizations coded as herpes zoster (HR, 0.35; 95% CI, 0.24-0.51) were less likely among vaccine recipients. CONCLUSIONS: Among immunocompetent community-dwelling adults aged 60 years or older, receipt of the herpes zoster vaccine was associated with a lower incidence of herpes zoster. The risk was reduced among all age strata and among individuals with chronic diseases.
机译:背景:在美国,每年发生约一百万次带状疱疹发作。尽管先证数据提供了带状疱疹疫苗在理想情况下在特定研究人群中起作用的证据,但仍需要在野外条件下对该疫苗进行评估。目的:评估一般实践环境中个体接受带状疱疹疫苗后带状疱疹的风险。设计,地点和参与者:一项从2007年1月1日至2009年12月31日的回顾性队列研究,研究对象为参加南加州凯泽永久医疗保健计划的人员。参加者为年龄在60岁以上,具有免疫能力的社区居民。接种人群中的75,761名成员与227,283名未接种疫苗的成员的年龄匹配(1:3)。主要观察指标:带状疱疹的发病率。结果:带状疱疹疫苗的接种者更可能是白人,妇女,门诊就诊次数更多,慢性病更少。在130,415人年中,接种疫苗的人中带状疱疹病例数为828(每1000人年6.4; 95%的置信区间[CI]为5.9-6.8),而在未接种人员中,355,659人年中为4606(每1000人年13.0; 95%CI,12.6-13.3)。在调整后的分析中,接种疫苗可降低带状疱疹的风险(危险比[HR]为0.45; 95%CI为0.42-0.48);这种减少发生在所有年龄阶层和患有慢性疾病的个体中。带状疱疹的风险因接种状况的不同而比不相关的急性医疗状况的风险差异更大,这表明带状疱疹的结果并非由于偏见所致。在疫苗接种者中,眼科带状疱疹(HR,0.37; 95%CI,0.23-0.61)和住院编码为带状疱疹(HR,0.35; 95%CI,0.24-0.51)的可能性较小。结论:在60岁或以上具有免疫能力的社区居住的成年人中,带状疱疹疫苗的接种与带状疱疹的发生率较低有关。在所有年龄段以及患有慢性疾病的个体中,风险都降低了。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号